Standout Papers

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Meta... 2021 2026 2022 2024214
  1. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas (2021)
    Funda Meric‐Bernstam, Randy F. Sweis et al. Clinical Cancer Research

Immediate Impact

1 by Nobel laureates 5 from Science/Nature 61 standout
Sub-graph 1 of 23

Citing Papers

STING licensing of type I dendritic cells potentiates antitumor immunity
2024 Standout
Emerging nitric oxide gas‐assisted cancer photothermal treatment
2024 Standout
1 intermediate paper

Works of Matthew Ingham being referenced

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
2021 Standout

Author Peers

Author Last Decade Papers Cites
Matthew Ingham 272 338 291 47 765
Elena Muraro 175 447 203 40 842
Shigehiro Yagishita 284 532 339 63 974
Erin L. Schenk 286 426 296 55 802
Man Jiang 218 377 247 66 867
Shanshan Liu 241 192 309 40 718
Mikinori Miyazaki 200 368 297 32 876
Huihua Zhang 103 361 316 37 740
Trevor Clancy 90 311 429 37 852
Shogo Kumagai 374 431 195 36 960
Qingyang Feng 257 440 419 58 987

All Works

Loading papers...

Rankless by CCL
2026